Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Acquires 32,527 Shares of Cencora, Inc. (NYSE:COR)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in Cencora, Inc. (NYSE:COR - Free Report) by 6,505.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 33,027 shares of the company's stock after buying an additional 32,527 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in Cencora were worth $7,767,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. New Millennium Group LLC purchased a new stake in shares of Cencora in the 2nd quarter valued at $26,000. TCTC Holdings LLC acquired a new stake in shares of Cencora in the first quarter valued at about $29,000. TFO Wealth Partners LLC acquired a new stake in shares of Cencora in the first quarter valued at about $30,000. LRI Investments LLC acquired a new stake in shares of Cencora in the first quarter valued at about $31,000. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the second quarter valued at about $30,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insider Activity at Cencora

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares of the company's stock, valued at approximately $4,806,388,800. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares of the company's stock, valued at $2,656,970.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the firm's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the sale, the insider now directly owns 19,980,000 shares of the company's stock, valued at $4,806,388,800. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 4,461,153 shares of company stock worth $1,073,075,720 in the last three months. Insiders own 15.80% of the company's stock.

Cencora Stock Down 0.9 %

COR stock traded down $1.98 during midday trading on Wednesday, reaching $229.79. 65,695 shares of the company were exchanged, compared to its average volume of 1,399,833. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. Cencora, Inc. has a 1-year low of $182.75 and a 1-year high of $247.66. The stock's 50-day simple moving average is $231.91 and its 200 day simple moving average is $230.73. The company has a market cap of $45.83 billion, a price-to-earnings ratio of 25.36, a price-to-earnings-growth ratio of 1.40 and a beta of 0.44.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company's revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period last year, the firm posted $2.92 earnings per share. On average, equities analysts forecast that Cencora, Inc. will post 13.63 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on COR. Leerink Partners dropped their price objective on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday, October 7th. Robert W. Baird reduced their price target on shares of Cencora from $287.00 to $283.00 and set an "outperform" rating on the stock in a research report on Friday, September 6th. Wells Fargo & Company increased their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 1st. StockNews.com cut shares of Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Finally, JPMorgan Chase & Co. raised their target price on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a report on Wednesday, August 21st. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $259.44.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.